News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eden Biodesign Assists Momotaro-Gene, Inc. to Commence Human Clinical Trials Less Than 12 Months After Being Engaged to Produce a Recombinant Adenovirus Vector from a New Cell Line



7/14/2010 10:35:33 AM

LIVERPOOL, England & OKAYAMA, Japan--(BUSINESS WIRE)--Eden Biodesign Ltd. and Momotaro-Gene, Inc. today announced the success of a collaborative global project that demonstrated Eden’s capabilities to work quickly to develop an adenoviral manufacturing process providing Momotaro-Gene with drug substance and vialed drug product ready for their clinical trial within 12 months. Momotaro-Gene, Inc. already cleared its first IND (Investigational New Drug) application with this drug product to the FDA and expects to start its First-In-Man clinical trial at Mt. Sinai Hospital, USA, this month.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES